Cargando…

Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study

OBJECTIVES: To evaluate the short-term (12 weeks) safety and utilisation of rivaroxaban prescribed to new-user adult patients for the treatment of deep vein thrombosis and pulmonary embolism and for the prevention of recurrent deep vein thrombosis and pulmonary embolism in a secondary care setting i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evans, Alison, Davies, Miranda, Osborne, Vicki, Roy, Debabrata, Shakir, Saad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640735/ https://www.ncbi.nlm.nih.gov/pubmed/33148732 http://dx.doi.org/10.1136/bmjopen-2020-038102

Ejemplares similares

Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
por: Evans, Alison, et al.
Publicado: (2020)

Use of oral rivaroxaban in cerebral venous thrombosis
por: Maqsood, Muhammad, et al.
Publicado: (2020)

Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment
por: Davies, Miranda, et al.
Publicado: (2020)

Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J’xactly) study
por: Okumura, Yasuo, et al.
Publicado: (2018)

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment
por: Osborne, Vicki, et al.
Publicado: (2020)

Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China
por: Yang, Li, et al.
Publicado: (2020)

Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban
por: Naito, Tomoyuki, et al.
Publicado: (2018)

Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management
por: Osborne, Vicki, et al.
Publicado: (2020)

Observational assessment of safety in seroquel (OASIS): a specialist cohort event monitoring (SCEM) study in England
por: Osborne, Vicki, et al.
Publicado: (2020)

Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
por: Thaler, Johannes, et al.
Publicado: (2015)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Reversal of Bioprosthetic Aortic Valve Thrombosis Using Rivaroxaban—A Case Report
por: Sharma, Harish, et al.
Publicado: (2020)

A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events
por: Dhanda, Sandeep, et al.
Publicado: (2021)

Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban
por: Yang, Hyeyoung, et al.
Publicado: (2016)

Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care
por: Peacock, W. Frank, et al.
Publicado: (2019)

Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?
por: Dhanda, Sandeep, et al.
Publicado: (2022)

Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies
por: Wang, Yuqi, et al.
Publicado: (2013)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

Decreased Rivaroxaban Levels in a Patient with Cerebral Vein Thrombosis Receiving Phenytoin
por: Becerra, Ana F., et al.
Publicado: (2017)

A Case of Renal Vein Thrombosis Associated With COVID-19 Treated With Rivaroxaban
por: Asleson, Louise, et al.
Publicado: (2022)

Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study
por: Ageno, Walter, et al.
Publicado: (2022)

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
por: Diener, H.‐C., et al.
Publicado: (2015)

Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment
por: Koitabashi, Norimichi, et al.
Publicado: (2015)

Rivaroxaban for the Treatment of Pulmonary Embolism
por: Vanassche, Thomas, et al.
Publicado: (2013)

Efficacy of rivaroxaban for pulmonary embolism
por: Jia, Juan, et al.
Publicado: (2019)

An Atypical Case of Morbid Obesity, Presenting With Deep Vein Thrombosis and Pulmonary Embolism
por: Chitkara, Akshit, et al.
Publicado: (2020)

High fibrinogen and mixed proximal and distal thrombosis are associated with the risk of residual venous thrombosis in patients with posttraumatic deep vein thrombosis
por: Liu, Yating, et al.
Publicado: (2023)

Superficial Vein Thrombosis and Severe Varicose Veins Complicating Venous Thromboembolism
por: Lee, Sun Hwa, et al.
Publicado: (2019)

A Case of Isolated Unilateral Right Renal Vein Thrombosis Associated with Bilateral Pulmonary Embolism Treated with Rivaroxaban a Direct-Acting Oral Anticoagulant
por: Matta, Anthony, et al.
Publicado: (2019)

Successful treatment with rivaroxaban of an extended deep vein thrombosis complicated by pulmonary embolism in a patient with familial antithrombin III deficiency: a case report
por: Appignani, Marianna, et al.
Publicado: (2019)

Splenic artery embolization in a woman with bleeding gastric varices and splenic vein thrombosis: a case report
por: Saugel, Bernd, et al.
Publicado: (2010)

Poor response to rivaroxaban in nephrotic syndrome with acute deep vein thrombosis: A case report
por: Li, Yan, et al.
Publicado: (2019)

Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis
por: Zhou, Haonan, et al.
Publicado: (2023)

Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay
por: Schenk, B., et al.
Publicado: (2016)

Rivaroxaban for the treatment of cerebral venous thrombosis
por: Esmaeili, Sara, et al.
Publicado: (2021)

Effective single-drug approach is welcomed for deep-vein thrombosis treatment
Publicado: (2010)

Clinical Characteristics and Management of Ovarian Vein Thrombosis: A Case Series
por: Alsheef, Mohammed, et al.
Publicado: (2022)

Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study
por: Jaksa, Ashley, et al.
Publicado: (2022)

The association between iliac vein compression degree and characteristics of first diagnosed left lower extremity deep vein thrombosis
por: Shi, Yadong, et al.
Publicado: (2022)

Isolated proximal greater saphenous vein thrombosis and the risk of propagation to deep vein thrombosis and pulmonary embolism
por: Kim, Samuel H, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ebkuf524gcpfh1ckf71g03iodq